The government of Khyber Pakhtunkhwa has launched the treatment of poor blood Cancer patient, namely (Chronic myeloid leukaemia) project phase-II, under joint public-private partnership with Novartis Pharma Pakistan.
Under the second phase, the provincial government has been allocated Rs 600million for Chronic myeloid leukaemia (CML) project, a form of blood cancer for three-year, which would be spent Rs 200million for each year for treatment of poor blood cancer patients in the province. The CML project, launched a three years back, by the previous government, under which more than 866 blood cancer patients, successfully completed their medication course and other required screening tests, said Professor Dr Abid Jameel, a focal person of the CML project, while talking to this scribe here on Sunday.
Of the total registered patients of blood cancer, he said 493 male and 373 female got treatment under the project. "Only five blood cancer patients have been died during treatment with morality ratio of 7%, while over 90% patients have become treated successfully from the disease, Dr Jameel said. He said around 60 percent genies have been completed cured.
According to study, he said the people mostly suffered from blood cancer during age of 40, while treatment of blood cancer is much expensive, as Rs 119,000 being required for completion diagnosis and treatment of a blood cancer patient. Under the preliminary phase-I, he informed that a total of Rs 8.1 billion has been allocated for 8 years for the CML project, out of which 94 percent has been contributed by Novartis Pharma, while provincial government share only six percent in the project.
The CML project, Dr Jameel said, had been recognised at national and international level. He said the project funds have been utilised in transparent and fair manner, as the independent monitoring unit of KP government also declared it as transparent and vibrant healthcare program. He furthermore informed that special chip cards have been issued to blood cancer patients, through which they are easily got medicines and other treatments stuffs, which proved more transparency in the project. Similarly, he said the patients are being informed through Short Messages Service (SMS) about the medicines course and other relevant pre-cautionary advises by physicians.
Dr Jameel said that about 20 to 25 new patients have been diagnosed suffering from blood cancer every month, due to which yearly ratio of patients touched around 250-300 in the province. He informed that physicians are adopted three main function during treatment of blood cancer patients, these include prevention, treatment, cure, and resistance stage. According to official hand out of health department, stated that there are around 12000 patients of Chronic myeloid leukaemia (CML) in Pakistan, while a total blood cancer patient in Khyber Pakhtunkhwa, is nearly 800-1000, the number is soaring with the passage due to expensive treatment of the disease.
Under the phase-I, the official note said the provincial government agreed to support two month therapy for the patients worth Rs 190million per year for 3 years, where as Novartis supports the remaining 10 months therapy. The public-private partnership help government to achieve their vision "healthier KP" and giving benefit to the patients from a better working healthcare delivery system particularly poorest.
KP government in collaboration with Novartis Pharma is providing free medicines to needy patients suffering from blood cancer (CML) in Khyber Pakhtunkhwa, the CML project phase-I cost of Rs 8.1billion for 8years, giving support to the patients at zero cost. In this regard, Government of Khyber Pakhtunkhwa and Novartis signed a agreement in 2011, which extended to next three year, by launching phase-II here on Thursday. The cost of one month dosage of the medicine was Rs 120,000, and annual cost of over Rs 4.1million, which was not affordable by the poor patients and the provincial government was also lacking resources. Therefore, KP government and Novartis MOU, will provide free of cost medicine to patients.
Comments
Comments are closed.